<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00765206</url>
  </required_header>
  <id_info>
    <org_study_id>18134</org_study_id>
    <secondary_id>CL2008-02</secondary_id>
    <secondary_id>P07814</secondary_id>
    <nct_id>NCT00765206</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study Comparing Zegerid速 and Prilosec OTC速 (Study CL2008-02)(P07814)(COMPLETED)</brief_title>
  <official_title>Randomized, Crossover Pharmacodynamic Study Comparing the Effects of Zegerid速 (20 mg Omeprazole/Sodium Bicarbonate) and Prilosec OTC速 Tablets (20 Mg-equivalent Omeprazole)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valeant Pharmaceuticals International, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label randomized crossover design study. 60 participants will be evaluated on Day 1 to
      compare effects on stomach acid; 30 participants will continue treatment for 7 days and will
      have repeat evaluations at Day 7.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled participants were divided into 2 groups, with 30 participants in each group.

      Group 1: This group was randomized into a single-dose, 2-way crossover design. These
      participants received single administrations (day 1 dosing only) of Zegerid OTC Capsules, and
      Prilosec OTC Tablets (both at a 20 mg omeprazole dose), in a 2-way randomized order, with a
      minimum of a 2-week washout period between treatment legs. This group underwent a 24-hour
      intragastric pH study on each of the 2 dosing occasions.

      Group 2: This group was randomized into a 2-way crossover design in which they received 7
      days administration of Zegerid OTC Capsules and Prilosec OTC Tablets, respectively. As with
      the prior group, there was a minimum of a 2-week washout period between treatment legs.
      Participants assigned to this treatment group underwent 24-hour intragastric pH recordings on
      the days which they received their 1st and last (7th) dose of the two treatment drugs.

      In addition to the above detailed procedures, all participants (both groups) underwent a
      24-hour baseline intragastric pH study prior to starting their randomized treatments. This
      study design enabled all 60 participants to be evaluated for effects of the first dose of
      Prilosec OTC Tablets and Zegerid OTC Capsules on change in intragastric pH during the
      subsequent 24-hour period following the first dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration</measure>
    <time_frame>Baseline and 7 days</time_frame>
    <description>The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Gastric Acid</condition>
  <condition>Human Experimentation</condition>
  <arm_group>
    <arm_group_label>Zegerid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Omeprazole 20 mg /sodium bicarbonate 1100 mg over-the-counter (OTC) Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prilosec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omeprazole magnesium 20 mg OTC tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole/sodium bicarbonate</intervention_name>
    <description>Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.</description>
    <arm_group_label>Zegerid</arm_group_label>
    <other_name>Zegerid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole magnesium (20 mg equivalent)</intervention_name>
    <description>Single dose of omeprazole magnesium per day for either 1 or 7 days.</description>
    <arm_group_label>Prilosec</arm_group_label>
    <other_name>Prilosec OTC Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal subjects who are 18-65 years of age.

          -  Non-childbearing potential females or those using birth control.

        Exclusion Criteria:

          -  History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump
             inhibitors

          -  History of significant gastrointestinal disease

          -  Any significant medical illness

          -  Gastrointestinal disorder or surgery leading to impaired drug absorption

          -  Currently using gastrointestinal medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>September 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>August 28, 2009</results_first_submitted>
  <results_first_submitted_qc>April 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 30, 2010</results_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Omeprazole, sodium bicarbonate drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>60 participants were enrolled: 30 participants were randomized to 1-Day Dosing and 30 participants were randomized to 7-Day Dosing. This was a crossover study, ie, participants in both groups received one treatment [Zegerid or Prilosec], followed by a 2-week washout period, followed by the other treatment [Prilosec or Zegerid].</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zegerid First, Then Prilosec (1- Day Dosing)</title>
          <description>Participants received Zegerid Over-the-counter (OTC) Capsules (omeprazole 20 mg and sodium bicarbonate 1100 mg) in the first intervention and Prilosec OTC Tablets (omeprazole 20 mg) in the second intervention (after washout period)</description>
        </group>
        <group group_id="P2">
          <title>Prilosec First, Then Zegerid (1-Day Dosing)</title>
          <description>Participants received Prilosec OTC Tablets (omeprazole 20 mg) in the first intervention and Zegerid OTC Capsules (omeprazole 20 mg and sodium bicarbonate 1100 mg) in the second intervention (after washout period)</description>
        </group>
        <group group_id="P3">
          <title>Zegerid First, Then Prilosec ( 7-Day Dosing)</title>
          <description>Participants received Zegerid OTC Capsules (omeprazole 20 mg and sodium bicarbonate 1100 mg) in the first intervention and Prilosec OTC Tablets (omeprazole 20 mg) in the second intervention (after washout period)</description>
        </group>
        <group group_id="P4">
          <title>Prilosec First, Then Zegerid (7-Day Dosing)</title>
          <description>Participants received Prilosec OTC Tablets (omeprazole 20 mg) in the first intervention and Zegerid OTC Capsules (omeprazole 20 mg and sodium bicarbonate 1100 mg) in the second intervention (after washout period)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 14 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration</title>
        <description>The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.</description>
        <time_frame>Baseline and 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zegerid</title>
            <description>Participants in the 7-Day Dosing group. Measurements taken on the 7th day of Zegerid administration.</description>
          </group>
          <group group_id="O2">
            <title>Prilosec</title>
            <description>Participants in the 7-Day Dosing group. Measurements taken on the 7th day of Prilosec administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Median 24-hour Intragastric pH on the 7th Day of Drug Administration</title>
          <description>The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.</description>
          <units>pH scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.575" spread="1.349" lower_limit="1.33" upper_limit="5.98"/>
                    <measurement group_id="O2" value="3.980" spread="1.433" lower_limit="1.37" upper_limit="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline in pH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.165" spread="1.360" lower_limit="0.03" upper_limit="4.75"/>
                    <measurement group_id="O2" value="2.550" spread="1.478" lower_limit="-0.89" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Zegerid</title>
          <description>Subjects who received a single dose of Zegerid per day for either 1 or 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Prilosec</title>
          <description>Subjects who received a single dose of Prilosec per day for either 1 or 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Schering-Plough HealthCare Products, Inc. reserves all publication and
presentation rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

